**PATENT ASSIGNMENT**

Electronic Version v1.1
Stylesheet Version v1.1

<table>
<thead>
<tr>
<th>SUBMISSION TYPE:</th>
<th>NEW ASSIGNMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>NATURE OF CONVEYANCE:</td>
<td>ASSIGNMENT</td>
</tr>
</tbody>
</table>

**CONVEYING PARTY DATA**

<table>
<thead>
<tr>
<th>Name</th>
<th>Execution Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detlef Kozian</td>
<td>06/20/2008</td>
</tr>
<tr>
<td>Matthias Herrmann</td>
<td>06/10/2008</td>
</tr>
</tbody>
</table>

**RECEIVING PARTY DATA**

<table>
<thead>
<tr>
<th>Name:</th>
<th>Sanofi-Aventis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Street Address:</td>
<td>174 Avenue de France</td>
</tr>
<tr>
<td>City:</td>
<td>Paris</td>
</tr>
<tr>
<td>State/Country:</td>
<td>FRANCE</td>
</tr>
<tr>
<td>Postal Code:</td>
<td>75013</td>
</tr>
</tbody>
</table>

**PROPERTY NUMBERS Total: 1**

<table>
<thead>
<tr>
<th>Property Type</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Number</td>
<td>12089627</td>
</tr>
</tbody>
</table>

**CORRESPONDENCE DATA**

Fax Number: (908)231-2626
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 908-231-4854
Email: maribel.mendez@sanofi-aventis.com

Correspondent Name: William C. Coppola
Address Line 1: Route 202-206
Address Line 4: Bridgewater, NEW JERSEY 08807

**ATTORNEY DOCKET NUMBER:** DE2005/050 US CNT

**NAME OF SUBMITTER:** Maribel Mendez

Total Attachments: 1
source=12_089627_Assignment#page1.tif
ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

1) Dr. Detlef Kozian, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
2) Dr. Matthias Herrmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany

The inventors are citizens of Germany

hereby sell, assign, and transfer unto sanofi-aventis,

a corporation organized under the laws of France,

located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 12/089,627

filed: April 9, 2008

entitled: EGLN2 Variants and Use thereof in Preventing or Treating Thromboembolic Disorders and Coronary Heart Diseases

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):

1st. __________________________ Date: 20 June 2008

2nd. __________________________ Date: 28 Jun 2008

PATENT
REEL: 021315 FRAME: 0715

RECORDED: 07/30/2008